Q4 EPS Estimates for Exact Sciences Decreased by Analyst

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Equities research analysts at Leerink Partnrs cut their Q4 2025 earnings per share estimates for shares of Exact Sciences in a report released on Wednesday, November 6th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $0.14 for the quarter, down from their prior estimate of $0.22. The consensus estimate for Exact Sciences' current full-year earnings is ($0.87) per share.

Several other research analysts also recently commented on the company. BTIG Research decreased their price objective on Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a research note on Wednesday. Wells Fargo & Company began coverage on Exact Sciences in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $75.00 price objective on the stock. Citigroup decreased their price objective on Exact Sciences from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Wednesday. Jefferies Financial Group lifted their target price on Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Robert W. Baird dropped their price target on Exact Sciences from $70.00 to $67.00 and set an "outperform" rating for the company in a research note on Wednesday. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $75.06.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS traded down $2.18 during trading on Thursday, hitting $52.54. The company had a trading volume of 2,893,175 shares, compared to its average volume of 2,596,111. The stock has a 50 day simple moving average of $67.14 and a 200 day simple moving average of $56.65. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. Exact Sciences has a 12 month low of $40.62 and a 12 month high of $79.62. The firm has a market capitalization of $9.71 billion, a P/E ratio of -57.00 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The company had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. The firm's quarterly revenue was up 12.8% compared to the same quarter last year.

Insider Activity at Exact Sciences

In related news, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares of the company's stock, valued at approximately $893,060. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.36% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Exact Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Huntington National Bank lifted its position in shares of Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock worth $27,000 after purchasing an additional 352 shares during the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Exact Sciences during the third quarter worth $35,000. Vestor Capital LLC bought a new stake in shares of Exact Sciences during the third quarter worth $46,000. V Square Quantitative Management LLC bought a new stake in shares of Exact Sciences during the third quarter worth $47,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Exact Sciences during the second quarter worth $29,000. 88.82% of the stock is owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.